Detailed Information

Cited 7 time in webofscience Cited 6 time in scopus
Metadata Downloads

Enhanced Systemic Anti-Angiogenic siVEGF Delivery Using PEGylated Oligo-D-arginine

Full metadata record
DC Field Value Language
dc.contributor.authorChung, Jee Young-
dc.contributor.authorUl Ain, Qurrat-
dc.contributor.authorLee, Hyun Lin-
dc.contributor.authorKim, So-Mi-
dc.contributor.authorKim, Yong-Hee-
dc.date.accessioned2021-07-30T05:33:12Z-
dc.date.available2021-07-30T05:33:12Z-
dc.date.created2021-05-12-
dc.date.issued2017-09-
dc.identifier.issn1543-8384-
dc.identifier.urihttps://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/5382-
dc.description.abstractAngiogenesis mainly mediated by upregulation of vascular endothelial growth factor (VEGF) provides a hallmark of rapidly proliferating tumor cells and an essential component of the tumor growth and microenvironment, making it a targetable process for antitumor therapy. RNA interference (RNAi) provides a very effective tool for developing antitumor therapies; however, its application to date has been hampered due to the lack of efficient small interfering RNA (siRNA) delivery systems in vivo. Here, we report a polymeric gene carrier system based on PEGylation of a cationic cysteine-ended 9-mer arginine oligopeptide (CR9C), which provides effective siRNA systemic delivery and specifically suppresses VEGF (siVEGF). The PEG500-CR9C/siVEGF oligopeptoplex provided improved blood circulation, enhanced protection from serum proteases, reduced uptake in the liver and kidneys, enhanced tumor targeting, and down-regulated intratumoral VEGF level, which comprehensively resulted in improved antitumor efficacy without significant toxicity in vivo. PEG500-CR9C has a great potential for safe and efficient siRNA delivery with diverse applications.-
dc.language영어-
dc.language.isoen-
dc.publisherAMER CHEMICAL SOC-
dc.titleEnhanced Systemic Anti-Angiogenic siVEGF Delivery Using PEGylated Oligo-D-arginine-
dc.typeArticle-
dc.contributor.affiliatedAuthorKim, Yong-Hee-
dc.identifier.doi10.1021/acs.molpharmaceut.7b00282-
dc.identifier.scopusid2-s2.0-85028817161-
dc.identifier.wosid000410005100019-
dc.identifier.bibliographicCitationMOLECULAR PHARMACEUTICS, v.14, no.9, pp.3059 - 3068-
dc.relation.isPartOfMOLECULAR PHARMACEUTICS-
dc.citation.titleMOLECULAR PHARMACEUTICS-
dc.citation.volume14-
dc.citation.number9-
dc.citation.startPage3059-
dc.citation.endPage3068-
dc.type.rimsART-
dc.type.docTypeArticle-
dc.description.journalClass1-
dc.description.isOpenAccessN-
dc.description.journalRegisteredClassscie-
dc.description.journalRegisteredClassscopus-
dc.relation.journalResearchAreaResearch & Experimental Medicine-
dc.relation.journalResearchAreaPharmacology & Pharmacy-
dc.relation.journalWebOfScienceCategoryMedicine, Research & Experimental-
dc.relation.journalWebOfScienceCategoryPharmacology & Pharmacy-
dc.subject.keywordPlusSMALL-INTERFERING RNA-
dc.subject.keywordPlusSIRNA DELIVERY-
dc.subject.keywordPlusGENE DELIVERY-
dc.subject.keywordPlusIN-VIVO-
dc.subject.keywordPlusCANCER-THERAPY-
dc.subject.keywordPlusPEPTIDE-
dc.subject.keywordPlusNANOPARTICLES-
dc.subject.keywordPlusCIRCULATION-
dc.subject.keywordPlusPOLYPLEXES-
dc.subject.keywordPlusCARRIER-
dc.subject.keywordAuthorangiogenesis-
dc.subject.keywordAuthorenhanced permeability and enhanced effect-
dc.subject.keywordAuthorsiVEGF delivery-
dc.subject.keywordAuthorPEGylation-
dc.subject.keywordAuthorantitumor therapy-
dc.identifier.urlhttps://pubs.acs.org/doi/10.1021/acs.molpharmaceut.7b00282-
Files in This Item
Go to Link
Appears in
Collections
서울 공과대학 > 서울 생명공학과 > 1. Journal Articles

qrcode

Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.

Related Researcher

Researcher Kim, Yong Hee photo

Kim, Yong Hee
COLLEGE OF ENGINEERING (DEPARTMENT OF BIOENGINEERING)
Read more

Altmetrics

Total Views & Downloads

BROWSE